Oral News and Research

RSS

New data shows consolidation of interferon-free revolution in HCV treatment

New data presented at the International Liver Congress 2012 shows consolidation of the interferon-free (IFN) revolution in HCV treatment. The much anticipated data from a number of clinical trials confirm that combinations of antivirals offer the hope of shorter, more effective treatment with fewer side effects.

20 Apr 2012

Bristol-Myers Squibb announces results from daclatasvir plus asunaprevir Phase II HCV study

Bristol-Myers Squibb Company today announced results from a Phase II study in which treatment with an all-oral, dual direct-acting antiviral (DAA) regimen of daclatasvir, an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor, achieved undetectable viral load 24 weeks post-treatment (SVR24) in 77% (33/43) of difficult-to-treat genotype 1b hepatitis C (HCV) patients.

20 Apr 2012

Viewpoints: Bishops find fault with GOP budget; Pelosi on court's role in health law

In February, the Catholic Church attempted to impose its opposition to birth control on its employees, upsetting Democrats and the left. This week, the Church is criticizing Republicans, acting in the highest tradition of its social mission by speaking out against spending cuts on programs for the poor.

20 Apr 2012

Omega-3 fatty acids inhibit detrimental effects of smoking on arterial function

Omega-3 fatty acids may help to reduce the physical harm caused by smoking, according to a new study presented today at the World Congress of Cardiology.

20 Apr 2012

Patients with head and neck cancer can benefit from swallowing exercises

Mount Sinai School of Medicine researchers have found that targeted swallowing exercises can help alleviate swallowing dysfunction - a debilitating side effect in people undergoing chemoradiation therapy (CRT) for head and neck cancer.

20 Apr 2012

ESC launches European Heart Journal: Acute Cardiovascular Care

The European Society of Cardiology (ESC) announced today the launch of the European Heart Journal: Acute Cardiovascular Care, the organisation's official journal of the ESC Working Group on Acute Cardiac Care.

20 Apr 2012

Inform Genomics completes first phase in oral mucositis risk prediction study

Inform Genomics, Inc., a private company focused on developing novel platforms of personalized medicine products for cancer supportive care and inflammatory diseases, today announced the completion of the first phase of product development to predict a patient's risk of developing oral mucositis after receiving high dose chemotherapy prior to hematopoietic stem cell transplant.

19 Apr 2012

Final data from Santaris’ miravirsen Phase 2a trial on HCV to be presented at ILC 2012

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will present final data from a Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided robust dose-dependent anti-viral activity with a mean reduction of 2 to 3 logs from baseline in HCV RNA (log10 IU/mL) that was sustained well beyond the end of therapy.

19 Apr 2012

New studies on personalized lung cancer treatment presented at 3rd ELCC

Several new studies that may help doctors tailor lung cancer treatment to the characteristics of individual patients and of their tumors are being presented at the 3rd European Lung Cancer Conference in Geneva.

19 Apr 2012

Researchers present findings of retrospective analysis of microbicide study at international conference

"More than three years after reporting the primary results of HPTN 035, one of the last trials of the so-called first generation microbicides, researchers from the National Institutes of Health-funded Microbicide Trials Network (MTN) reported two new sets of findings gleaned" from the study data at the International Microbicides Conference in Sydney on Tuesday, an MTN press release states.

19 Apr 2012

Results from Presidio’s PPI-668 Phase 1a-1b trial on chronic HCV

Presidio Pharmaceuticals, Inc. announced results today from a Phase 1a-1b clinical trial of PPI-668, a potent, pan-genotypic HCV NS5A inhibitor being developed for the treatment of patients with chronic hepatitis C.

19 Apr 2012

Oral bacteria may cause problems in arthritis patients

The culprit behind a failed hip or knee replacements might be found in the mouth. DNA testing of bacteria from the fluid that lubricates hip and knee joints had bacteria with the same DNA as the plaque from patients with gum disease and in need of a joint replacement.

19 Apr 2012

Abbott reports positive results from LCIG Phase 3 trial for advanced Parkinson's disease

Abbott announced today the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel (LCIG).

18 Apr 2012

Simple, cost-effective saliva test to detect oral cancer

A Michigan State University surgeon is teaming up with a Lansing-area dental benefits firm on a clinical trial to create a simple, cost-effective saliva test to detect oral cancer, a breakthrough that would drastically improve screening and result in fewer people dying of the world's sixth most common cancer.

18 Apr 2012

Levodopa-carbidopa intestinal gel better than standard oral form to treat advanced Parkinson's disease

A levodopa-carbidopa intestinal gel (LCIG) works better than standard oral levodopa-carbidopa in reducing "off" time in patients with advanced Parkinson's disease.

18 Apr 2012

Early intervention of biologic therapies improves outcome for Crohn's disease

A large-scale study of medical claims data shows that introducing sophisticated biologic therapies early in the course of treatment for Crohn's disease improves response to medication and reduces the need for surgery.

18 Apr 2012

No added HIV risk with hormonal contraceptives

An HIV prevention trial that pre-dates the shift to antiretroviral (ARV)-based approaches is nonetheless helping to answer some of the most relevant and topical questions the field is facing today.

18 Apr 2012

Access reports positive interim results from MuGard Phase 4 clinical trial in oral mucositis

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology and oncology supportive care, announced interim results from its ongoing MuGard Phase 4 clinical trial in oral mucositis.

18 Apr 2012

Tumor size helps predict survival in node-negative breast cancer patients

Research from investigators at The Cancer Institute of New Jersey (CINJ), UMDNJ-School of Public Health (SPH) and UMDNJ-Robert Wood Johnson Medical School, indicates that tumor size stratified by age, race and hormone receptor status helps predict survival in node-negative breast cancer patients.

18 Apr 2012

International Microbicides Conference to discuss state of HIV prevention research

Researchers, activists and funders are meeting this week in Sydney to discuss the state of HIV prevention research. The biennial International Microbicides Conference, which was opened on Sunday evening by the Honorable Tanya Plibersek MP, Australian Minster of Health, is taking place amid renewed optimism about development and delivery of new HIV prevention options with the potential for ending the AIDS epidemic, including anti-retroviral based microbicides and pre-exposure prophylaxis.

17 Apr 2012

Oral News and Research

New data shows consolidation of interferon-free revolution in HCV treatment

Bristol-Myers Squibb announces results from daclatasvir plus asunaprevir Phase II HCV study

Viewpoints: Bishops find fault with GOP budget; Pelosi on court's role in health law

Omega-3 fatty acids inhibit detrimental effects of smoking on arterial function

Patients with head and neck cancer can benefit from swallowing exercises

ESC launches European Heart Journal: Acute Cardiovascular Care

Inform Genomics completes first phase in oral mucositis risk prediction study

Final data from Santaris’ miravirsen Phase 2a trial on HCV to be presented at ILC 2012

New studies on personalized lung cancer treatment presented at 3rd ELCC

Researchers present findings of retrospective analysis of microbicide study at international conference

Results from Presidio’s PPI-668 Phase 1a-1b trial on chronic HCV

Oral bacteria may cause problems in arthritis patients

Abbott reports positive results from LCIG Phase 3 trial for advanced Parkinson's disease

Simple, cost-effective saliva test to detect oral cancer

Levodopa-carbidopa intestinal gel better than standard oral form to treat advanced Parkinson's disease

Early intervention of biologic therapies improves outcome for Crohn's disease

No added HIV risk with hormonal contraceptives

Access reports positive interim results from MuGard Phase 4 clinical trial in oral mucositis

Tumor size helps predict survival in node-negative breast cancer patients

International Microbicides Conference to discuss state of HIV prevention research

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News